Novel Trial Design: A Report From the 19th Frontiers Symposium of ACCP

¹ University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Department of Medicine

^* To whom correspondence should be addressed. E-mail: ameerbcps{at}gmail.com.

	Abstract

Novel approaches to drug development along with incentives to reward risk undertaken during early drug development have been proposed to improve the medical product development process. The American College of Clinical Pharmacology held its 19th Frontiers Symposium in mid-2007 to provide a forum to share new knowledge about disease progression models and adaptive and other novel trial designs. These topics reflect the changing paradigm of drug development and regulatory innovation as outlined in the Food and Drug Administration FDA’s critical Path Initiative. This meeting report summarizes some of the presentations and panel discussions among academic, industrial, and regulatory participants regarding clinical trial design, including adaptive Bayesian approaches.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Biswas, D. D Liu, J J. Lee, and D. A Berry Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center Clinical Trials, June 1, 2009; 6(3): 205 - 216. [Abstract] [PDF]